Skip to main content
Top
Published in: Metabolic Brain Disease 8/2020

Open Access 01-12-2020 | Review Article

One drug to treat many diseases: unlocking the economic trap of rare diseases

Authors: Karolina Pierzynowska, Teresa Kamińska, Grzegorz Węgrzyn

Published in: Metabolic Brain Disease | Issue 8/2020

Login to get access

Abstract

There are two major problems with the development of therapies for rare diseases. First, among over 7000 such diseases, the vast majority are caused by genetic defects and/or include neurodegeneration, making them very difficult to treat. Second, drugs for rare diseases, so-called orphan drugs, are extremely expensive, as only a small number of patients are interested in purchasing them. This results in the appearance of a specific economic trap of rare diseases; namely, despite high biomedical, pharmaceutical and technological potential, the development of new orphan drugs is blocked by the economic reality. The purpose of this work was to find a potential solution that might resolve this economic trap of rare diseases. A literature review was conducted, and a hypothesis was formulated assuming that the use of one drug for the treatment of many rare diseases might overcome the economic trap. We provide examples showing that finding such drugs is possible. Thus, a possible solution for the problem of developing orphan drugs is presented. Further preclinical and clinical studies, although neither easy nor inexpensive, should verify whether the hypothesis regarding the possibility of unlocking the economic trap of rare diseases is valid.
Literature
go back to reference Ahmed MA, Okour M, Brundage R, Kartha RV (2019) Orphan drug development: the increasing role of clinical pharmacology. J Pharmacokinet Pharmacodyn 46:395–409CrossRef Ahmed MA, Okour M, Brundage R, Kartha RV (2019) Orphan drug development: the increasing role of clinical pharmacology. J Pharmacokinet Pharmacodyn 46:395–409CrossRef
go back to reference Al-Zaidy SA, Mendell JR (2019) From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr Neurol 100:3–11CrossRef Al-Zaidy SA, Mendell JR (2019) From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr Neurol 100:3–11CrossRef
go back to reference Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 14:130–146CrossRef Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 14:130–146CrossRef
go back to reference Chen T-H (2020) New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand? Int J Mol Sci 21:3297CrossRef Chen T-H (2020) New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand? Int J Mol Sci 21:3297CrossRef
go back to reference Concolino D, Deodato F, Parini R (2018) Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr 44(Suppl 2):120CrossRef Concolino D, Deodato F, Parini R (2018) Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr 44(Suppl 2):120CrossRef
go back to reference Gabig-Cimińska M, Jakóbkiewicz-Banecka J, Malinowska M et al (2015) Combined therapies for lysosomal storage diseases. Curr Mol Med 15:746–771CrossRef Gabig-Cimińska M, Jakóbkiewicz-Banecka J, Malinowska M et al (2015) Combined therapies for lysosomal storage diseases. Curr Mol Med 15:746–771CrossRef
go back to reference Hasima N, Ozpolat B (2014) Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer. Cell Death Dis 5:e1509CrossRef Hasima N, Ozpolat B (2014) Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer. Cell Death Dis 5:e1509CrossRef
go back to reference Hoy SM (2019) Onasemnogene abeparvovec: first global approval. Drugs 79:1255–1262CrossRef Hoy SM (2019) Onasemnogene abeparvovec: first global approval. Drugs 79:1255–1262CrossRef
go back to reference Jayasundara K, Hollis A, Krahn M, Mamdani M, Hoch JS, Grootendorst P (2019) Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet J Rare Dis 14:12CrossRef Jayasundara K, Hollis A, Krahn M, Mamdani M, Hoch JS, Grootendorst P (2019) Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet J Rare Dis 14:12CrossRef
go back to reference Lachmann RH (2020) Treating lysosomal storage disorders: what have we learnt? J Inherit Metab Dis 43:125–132CrossRef Lachmann RH (2020) Treating lysosomal storage disorders: what have we learnt? J Inherit Metab Dis 43:125–132CrossRef
go back to reference Levis M (2017) Midostaurin approved for FLT3-mutated AML. Blood 129:3403–3406CrossRef Levis M (2017) Midostaurin approved for FLT3-mutated AML. Blood 129:3403–3406CrossRef
go back to reference Luzzatto L, Hyry HI, Schieppati A et al (2018) Outrageous prices of orphan drugs: a call for collaboration. Lancet 392:791–794CrossRef Luzzatto L, Hyry HI, Schieppati A et al (2018) Outrageous prices of orphan drugs: a call for collaboration. Lancet 392:791–794CrossRef
go back to reference Malinowska M, Wilkinson FL, Langford-Smith KJ et al (2010) Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 5:e14192CrossRef Malinowska M, Wilkinson FL, Langford-Smith KJ et al (2010) Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 5:e14192CrossRef
go back to reference Melsheimer R, Geldhof A, Apaolaza I, Schaible T (2019) Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics 13:139–178PubMedPubMedCentral Melsheimer R, Geldhof A, Apaolaza I, Schaible T (2019) Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics 13:139–178PubMedPubMedCentral
go back to reference Nguengang Wakap S, Lambert DM, Olry A et al (2020) Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet 28:165–173CrossRef Nguengang Wakap S, Lambert DM, Olry A et al (2020) Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet 28:165–173CrossRef
go back to reference Pastuch-Gawołek G, Gillner D, Król E, Walczak K, Wandzik I (2019) Selected nucleos(t)ide-based prescribed drugs and their multi-target activity. Eur J Pharmacol 865:172747CrossRef Pastuch-Gawołek G, Gillner D, Król E, Walczak K, Wandzik I (2019) Selected nucleos(t)ide-based prescribed drugs and their multi-target activity. Eur J Pharmacol 865:172747CrossRef
go back to reference Pattali R, Mou Y, Li X-J (2019) AAV9 vector: a novel modality in gene therapy for spinal muscular atrophy. Gene Ther 26:287–295CrossRef Pattali R, Mou Y, Li X-J (2019) AAV9 vector: a novel modality in gene therapy for spinal muscular atrophy. Gene Ther 26:287–295CrossRef
go back to reference Pierzynowska K, Gaffke L, Cyske Z et al (2018a) Autophagy stimulation as a promising approach in treatment of neurodegenerative diseases. Metab Brain Dis 33:989–1008CrossRef Pierzynowska K, Gaffke L, Cyske Z et al (2018a) Autophagy stimulation as a promising approach in treatment of neurodegenerative diseases. Metab Brain Dis 33:989–1008CrossRef
go back to reference Pierzynowska K, Gaffke L, Hać A et al (2018b) Correction of Huntington's disease phenotype by genistein-induced autophagy in the cellular model. NeuroMolecular Med 20:112–123CrossRef Pierzynowska K, Gaffke L, Hać A et al (2018b) Correction of Huntington's disease phenotype by genistein-induced autophagy in the cellular model. NeuroMolecular Med 20:112–123CrossRef
go back to reference Pierzynowska K, Podlacha M, Gaffke L et al (2019) Autophagy-dependent mechanism of genistein-mediated elimination of behavioral and biochemical defects in the rat model of sporadic Alzheimer's disease. Neuropharmacology 148:332–346CrossRef Pierzynowska K, Podlacha M, Gaffke L et al (2019) Autophagy-dependent mechanism of genistein-mediated elimination of behavioral and biochemical defects in the rat model of sporadic Alzheimer's disease. Neuropharmacology 148:332–346CrossRef
go back to reference Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML (2018) A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med 7:3CrossRef Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML (2018) A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med 7:3CrossRef
go back to reference Schlander M, Beck M (2009) Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin 25:1285–1293CrossRef Schlander M, Beck M (2009) Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin 25:1285–1293CrossRef
go back to reference Schoser B, Hahn A, James E, Gupta D, Gitlin M, Prasad S (2019) A systematic review of the health economics of Pompe disease. Pharmacoecon Open 3:479–493CrossRef Schoser B, Hahn A, James E, Gupta D, Gitlin M, Prasad S (2019) A systematic review of the health economics of Pompe disease. Pharmacoecon Open 3:479–493CrossRef
go back to reference Senior M (2017) After Glybera's withdrawal, what's next for gene therapy? Nat Biotechnol 35:491–492CrossRef Senior M (2017) After Glybera's withdrawal, what's next for gene therapy? Nat Biotechnol 35:491–492CrossRef
go back to reference Solano ML, Fainboim A, Politei J, Porras-Hurtado GL, Martins AM, Moura Souza CF, Koch MF, Amartino H, Satizábal JM, Horovitz DDG, Medeiros PFV, Honjo RS, Charles Lourenço M (2020) Enzyme replacement therapy interruption in patients with mucopolysaccharidoses: recommendations for distinct scenarios in Latin America. Mol Genet Metab Rep 23:100572CrossRef Solano ML, Fainboim A, Politei J, Porras-Hurtado GL, Martins AM, Moura Souza CF, Koch MF, Amartino H, Satizábal JM, Horovitz DDG, Medeiros PFV, Honjo RS, Charles Lourenço M (2020) Enzyme replacement therapy interruption in patients with mucopolysaccharidoses: recommendations for distinct scenarios in Latin America. Mol Genet Metab Rep 23:100572CrossRef
go back to reference Stevens D, Claborn MK, Gildon BL, Kessler TL, Walker C (2020) Onasemnogene abeparvovec-xioi: gene therapy for spinal muscular atrophy. Ann Pharmacother 54:1001–1009CrossRef Stevens D, Claborn MK, Gildon BL, Kessler TL, Walker C (2020) Onasemnogene abeparvovec-xioi: gene therapy for spinal muscular atrophy. Ann Pharmacother 54:1001–1009CrossRef
go back to reference van Dussen L, Biegstraaten M, Hollak CEM, Dijkgraaf MGW (2014) Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet J Rare Dis 9:51CrossRef van Dussen L, Biegstraaten M, Hollak CEM, Dijkgraaf MGW (2014) Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet J Rare Dis 9:51CrossRef
go back to reference Zamora B, Maignen F, O'Neill P, Mestre-Ferrandiz J, Garau M (2019) Comparing access to orphan medicinal products in Europe. Orphanet J Rare Dis 14:95CrossRef Zamora B, Maignen F, O'Neill P, Mestre-Ferrandiz J, Garau M (2019) Comparing access to orphan medicinal products in Europe. Orphanet J Rare Dis 14:95CrossRef
go back to reference Zschocke J (2008) Dominant versus recessive: molecular mechanisms in metabolic disease. J Inherit Metab Dis 31:599–618CrossRef Zschocke J (2008) Dominant versus recessive: molecular mechanisms in metabolic disease. J Inherit Metab Dis 31:599–618CrossRef
Metadata
Title
One drug to treat many diseases: unlocking the economic trap of rare diseases
Authors
Karolina Pierzynowska
Teresa Kamińska
Grzegorz Węgrzyn
Publication date
01-12-2020
Publisher
Springer US
Published in
Metabolic Brain Disease / Issue 8/2020
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-020-00617-z

Other articles of this Issue 8/2020

Metabolic Brain Disease 8/2020 Go to the issue